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1571 ABSTRACT 
The present invention provides a system and method for 
creating on site, remote from a sterile environment, 
parenteral solutions in large volume parenteral containers 
for intravenous administration to a patient. In an embodi- 
ment, this system comprises an empty large volume con- 
tainer including at least one port for accessing an interior of 
the container. The port includes a sterilizing filter for ster- 
ilizing a fluid fed through the port into the container. A 
second container is provided including a solute and having 
means for coupling the second container to the large volume 
container and thereby providing fluid communication ther- 
ebetween allowing the solute to be received within the 
interior of the container. A sterile water source is also 
provided including means for placing the sterile water 
source in fluid communication with the port and allowing 
water to flow from the sterile water source into the interior 
of the container. This allows the solute, and sterile water that 
has been fed through the filter, to create a parenteral solution 
in the large volume parenteral container. 
47 Claims, 2 Drawing Sheets 
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SYSTEM FOR CREATING ON SITE, 
REMOTE FROM A STERILE 
volumes of solutions. These processes therefore are not 
conducive to the creation of large volume parenteral con- 
ENVIRONMENT, PARENTERAL SOLUTIONS tainers. 
SUMMARY OF THE INVENTION 
5 
BACKGROUND OF THE INVENTION 
The disclosed invention was funded, at least in part, by The present invention provides a system and method for 
NASA. creating on site, remote from a sterile environment, 
solutions for intravenous administration. More specifically, lo for intravenous administration to a patient. For example, the 
a space station, or other environment that is remote from 
sterile conditions, and used to create parenteral solutions in 
The present invention relates generally to the creation of parenteral in large parenteral containers 
the present invention relates to the creation on site, remote 
from sterile environments, of parenteral (intravenous) solu- 
present invention provides a system having a 
weight and volume 'lowing the system '0 be transported in 
tions. 
solutions, medicaments, agents, and the like to a patient 
intravenously (parenterally). These solutions are typically 
housed in containers, that are constructed from flexible 
plastic or glass, Typically, these solutions are 
housed in 
Of it is practice to administer many 15 large volume parenteral containers that can be used for 
administration to a patient. 
In an embodiment, this system comprises an empty large 
volume container including at least one port for accessing an 
having volume capacities of at least 2o interior of the container. The port includes a sterilizing filter 
A second container is provided including a solute and having 
means for coupling the second container to the large volume 
container and thereby providing fluid ther- 
ebetween allowing the to be received within the 
provided including means for placing the sterile water 
SOUICe in fluid with the port and allowing 
water to flow from the sterile water SOUICe into the interior 
30 has been fed through the filter, to create a parenteral solution 
in the large volume parenteral container. The resultant 
pareiteral solution, for example, saline, dextrose, or lactated 
ringer's, can then be administered to a patient, 
one liter, referred to as large volume containers, for a fluid fed through the Port into the container. 
Large volume parenteral containers 
solutions such as saline, dextrose, or lactated Ringer's. 
Although these solutions can be administered to a patient 
containers including the solution and the resultant product is 
then administered intravenously to the patient. To this end, 
the containers include additive or medication ports. Addi- 
the contents of the container. 
In use, the parenteral container is suspended and an IV 
line or other access means is utilized to access the container 
through the access port. Typically, the Iv line includes a 
alone, typically agents or medicaments are added to the 25 interior of the container. A sterile water Source is also 
tionally, the containers an Port for accessing of the container. This allows the solute, and sterile water that 
spike that is designed to pierce a membrane in the Port In an embodiment, a system is provided for creating on 
establishing fluid communication. A second end of the IV 35 site, remote Erom a sterile environment, solutions 
line is then directly inserted into the patient or coupled to a in a large volume parenteral container for intravenous 
Y-site that provides fluid communication with the patient. to a patient comprising an empty large vel- 
There are many situations wherein d~ to storage and/or ume container. The container includes at least two ports for 
weight limitations, or other concerns, it is not possible, or accessing an interior of the container. A first of the two ports 
Practical, to maintain an adequate inventory of Parenteral 40 includes a sterilizing filter for sterilizing a fluid fed through 
solutions that may be necessary. For example, space shuttles, the port into the container. A device housing a solute is also 
or the envisioned space Stations, have severe restrictions on provided that includes means that cooperates with a second 
weight and storage capacities. Although it may be desirable of the two ports so that the device can be coupled to the 
to stock a number Of intravenous SOlUtiOnS for use in XI container allowing fluid communication to be established 
emergency, or for medical treatment, it is not possible due to 45 between the interior of the container and the interior of the 
space and storage limitations to inventory a large volume of device. This allows the solute to be injected into the interior 
such solutions in many situations. Likewise, in other situa- of the container, Also provided is a sterile water SOuCe 
tions, such as in a combat zone, it may not be possible to including means for allowing the sterile water source to be 
transport the necessary parenteral solutions. 5o coupled to the first port allowing fluid communication to be 
Still further, even within health care facilities, storage and established between the sterile water source and the interior 
cost limitations may limit the inventory of product that is of the container. 
purchased and stored. Therefore, it may be desirable to In a preferred embodiment, the device includes a syringe 
compound on the Premises the necessary Parenteral Soh- body, that houses the solute, and a plunger that is used to 
tions. 55 force the solute out of the syringe body. 
Although it is known in certain applications to compound In another embodiment, a system for creating on site, 
and/or r~onst i tute  drugs prior to use, typically such recon- remote from a sterile environment, parenteral solutions in a 
stitution processes are performed in sterile conditions, for large volume parenteral container for intravenous adminis- 
example, under a laminar flow hood. Such sterile conditions tration to a patient is provided. n e  system includes an 
would not typically be present in the aforementioned space 60 empty large volume parenteral container, including at least 
station or combat zone. Likewise, current machinery for one port for accessing the interior of the container. The port 
creating large volume Parenteral Products not only requires includes a sterilizing filter for sterilizing a fluid fed through 
sterile conditions but also is quite bulky and heavy and not the port into the container. A second container is provided 
easily transportable. housing a solute in an interior thereof and having a first 
Furthermore, typically reconstitution processes usually 65 coupling member for coupling the second container to the 
either require a prepackaged intravenous solution, i.e., a bag port and establishing fluid communication between the 
of saline or dextrose, or can only be utilized to make small interior of the second container and the interior of the large 
5,490,848 
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volume parenteral container. The second container includes 
at a second end thereof a second coupling member. Also 
provided is a sterile water source for providing sterile water. 
The sterile water source includes a coupling member for 
coupling the sterile water source to the second coupling 
member of the second container and establishing fluid 
communication between the sterile water source and the 
interior of the second container. 
In an embodiment, the second container includes channels 
in an interior thereof. 
In an embodiment, the second container defines a circular 
flow path within an interior thereof. 
In an embodiment, the second container defines an elon- 
gated serpentine fluid flow path. 
In an embodiment of the present invention, the solute is 
a powder. 
In an embodiment of the present invention, the solute is 
a liquid. 
In an embodiment of the present invention, the solute 
includes a component chosen from the group consisting of 
dextrose, sodium chloride, and lactated Ringer’s. 
A method is also provided for preparing parenteral solu- 
tions on site, remote from a sterile environment. The method 
comprises the steps of: providing an empty large volume 
parenteral container including means for allowing the con- 
tainer to receive a solute and including a sterilizing filter; 
coupling a device including a solute to the container; caus- 
ing the solute to enter an interior of the container; and 
feeding sterile water into the container so that it flows 
through the sterilizing filter. 
In an embodiment of the method, the container includes 
two ports and the solute enters the interior of the container 
through one port and the sterile water enters the container 
through the second port. 
In an embodiment of the method, the device comprises a 
second container that is coupled to a port and the sterile 
water source is coupled to a second end of the second 
container so that sterile water is fed into an interior of the 
second container and the solute and sterile water then flow 
through the port and the filter into the container. 
In an embodiment of the method, the sterile water is fed 
into the container prior to the solute entering the container. 
In an embodiment of the method, the sterile water enters 
the container contemporaneously with the solute. 
In an embodiment of the method, the solute is a powder. 
In an embodiment of the method, the solute is a liquid 
concentrate. 
In an embodiment of the method, the solute includes a 
component chosen from the group consisting of: dextrose; 
sodium chloride; and lactated Ringer’s. 
In an embodiment of the method, a medicament is added 
to the resultant parenteral solution. 
In an embodiment of the method, the parenteral solution 
is administered intravenously to a patient. 
Additional features and advantages of the present inven- 
tion are described in, and will be apparent from, the detailed 
description of the presently preferred embodiments and from 
the drawings. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 illustrates a cross-sectional perspective view of an 
embodiment of the system for creating on site, remote from 
4 
a sterile environment, parenteral solutions in a large volume 
parenteral container. 
FIG. 2 illustrates a cross-sectional perspective view of 
another embodiment of the system of the present invention. 
FIG. 3 illustrates a cross-sectional view of another 
embodiment of the system of the present invention. 
FIG. 4 illustrates a cross-sectional perspective view of an 
embodiment of the device of the system of FIG. 3. 
FIG. 5 illustrates a cross-sectional view of a further 
embodiment of the device of the system of FIG. 3. 
FIG. 6 illustrates a cross-sectional view of another 
embodiment of the device of the system of FIG. 3. 
10 
15 DETAILED DESCFDTION OF THE, 
PRESENTLY PREFERRED EMBODIMENTS 
The present invention provides a system and method for 
formulating a predetermined amount of sterile solution for 
20 intravenous administration into a patient. The invention 
allows the transportation and storage of the necessary com- 
ponents to create a number of varied parenteral solutions 
that heretofore were not possible due to storage, weight, and 
space limitations. 
For example, in an environment such as a space station, 
space vehicle, or combat zone, the present invention allows 
the transportation and storage of the necessary components 
to create, as needed, parenteral solutions for use. Further- 
more, the present invention provides a method and process 
30 wherein sterile solutions, that can be administered to a 
patient, can be created and mixed in a non-sterile environ- 
ment without special equipment. Further, a relatively large 
number of parenteral solutions can be formulated using a 
relatively small number of bags and the like. 
In all of the embodiments of the present invention, empty 
large volume parenteral containers can be transported and 
then used to create containers housing parenteral solutions. 
For example, such end products as lactated Ringer’s, saline, 
half-normal saline, and 5% dextrose can be created. Further, 
40 these solutions can then be used with agents and medica- 
ments that are typically added to the solution to allow the 
infusion into a patient of products that heretofore were not 
possible in certain environments remote from sterile condi- 
tions. 
Referring now to FIG. 1, the system of the present 
invention includes an empty large volume parenteral con- 
tainer 10. The parenteral container 10 can be any size large 
volume parenteral container. For example, containers hous- 
ing one liter of solution can be used. The container 10 
includes a body 12 constructed from a flexible plastic 
material such as polyvinyl chloride, ethylene vinyl acetate, 
polyolefins, or combinations thereof. 
As illustrated, preferably, the container 10 includes a 
55 plurality of ports. Of course, the container 10 can include 
any number of ports and although four ports are illustrated, 
a greater or lesser number of ports can be provided. 
The first port 14 is a medicament or additive port that 
allows an agent or medicament to be injected into the 
60 interior 16 of the container 10. Although any type of port 
arrangement can be utilized, preferably, the first port 14 
includes a one way valve. An example of which is a one way 
valve manufactured by Burron Medical Corporation. The 
use of a one way valve allows a needleless, or blunt cannula 
65 to be used to inject a medicament into the interior 16 of the 
container 10. Additionally, a bidirectional valve available 
from Burton Medical Corporation can be used. Of course, if 
25 
35 
45 
50 . 
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desired, the port can include a typical pierceable membrane Sterile Water for Injection System (SWIS) developed by the 
and the port can be accessed by a pointed cannula needle. Sterimatics Division of Millipore Corporation for NASA. 
Additionally, a preslit resealable membrane and blunt can- Such a system includes a particulate filter, activated charcoal 
nula structure can be used. Such a preslit membrane and filter, cation bed, anion bed, and microbial filter. 
Cannula is disclosed in U.S. patent application ser. NO. 5 The container 10 includes a fourth port 34. The fourth port 
071147,414, “Preslit Injection Site and Associated Cannula”, 34 also allows a material to be injected into an interior 16 of 
abmdoned in favor of US. Patent application ser. No. the container 10. However, as discussed hereinafter, the 
07/539,278, the disclosures of which are incorporated herein fourth port 34 is specifically designed to receive the solute. 
by reference. The advantage of either needleless cannula Again, preferably the fourth port 34 includes a one way 
System is With respect to the improvements in Safety and valve to allow the solute to enter the interior 16 of the 
ease of use relative to prior practice. container 10, but prevents the contents in the interior of the 
The illustrated embodiment also includes a port protector container from flowing out of the container through the 
18. The port protector 18 ensures sterility of an interior of fourth port 34. Likewise, the fourth port 34 includes a port 
the port 14 until it is desired to access the container 10 protector 35. 
through the port 14. Preferably, to limit trash generation, the 15 AS illustrated in FIG. 1, the system also includes a 
port protector 18 is tethered to the first port 14. prefilled syringe 38. The prefilled syringe 38 includes the 
A second port 20, that functions as an access port, is solute 40. Within the container 10, the solute 40 is mixed 
provided that allows solution to flow out of the container 10. with the sterile water from the sterile water source 32 and 
The second port 20 can comprise a standard port that is creates a parenteral solution such as dextrose, saline, and 
accessed by a spike that is typically used on an IV admin- 20 lactated Ringer’s. 
istration set. Preferably, a bidirectional valve is provided The solute, as previously stated, when combined with 
within the Port 20 to allow fluid COmmuniCation between the sterile water, or other fluid creates a parenteral solution. As 
interior 16 of the container 10 and an Iv administration set. used herein, a solute refers to a composition that when 
Likewise, in the preferred embodiment illustrated, a port combined with water, or other fluid, creates a parenteral 
Protector 22 that is tethered to  the Port 20 is Provided. 25 solution. For example, the solute can be sodium chloride, 
A third port 24 is provided that also includes a port dextrose, or lactated Ringer’s. The solute can either be in a 
protector 26 tethered to the port. However, this port is liquid concentrated form or in a powder form. Due to 
coupled to a microbial or sterilizing filter 28 that is sealed sterilization concerns, the liquid concentrated form is prob- 
onto one end of the large volume parenteral container 10 and ably preferred. 
at the other end to the third port 24. The sterilizing filter 28 30 Even in the case of dextrose powders, it has been found 
Provides a fluid Path therethrough and terminates at an that the dissolution rates of the powder are such that con- 
Opening 30 in fluid COmInUniCatiOn With an interior 16 Of the tainers of parenteral solution can be created on an expedited 
container 10. AccordinglY, fluid that flows through the basis. For example, assuming that the sterile water source 32 
third Port 24 must flow WOWh the Sterilizing filter 28. The can produce no more than six liters of sterile water per hour, 
sterilizing filter 28 is utilized to sterilize the fluid that flows 35 the fill time of a one liter parenteral container would be ten 
through the third port 24 into the container 10. For example, minutes. Ten minutes is sufficient time to dissolve the 
a 0.22 micron sterilizing filter 28 can be utilized. necessary dextrose powder allowing a 5% dextrose solution 
Again, preferably, a bidirectional valve is utilized in the to be created that can then be administered intravenously. 
third port 24 to allow fluid flow into the interior 16 of the The sterile water source 32 can include a metering device 
container 10. As discussed in more detail hereinafter, the 40 (not shown) to ensme that only one liter of water is injected 
third Pod 24 and sterilizing filter 28 allow for water to flow into the container 10, if a one liter solution is to be created. 
into the interior 16 of the container 10 creating the parenteral Of course, the metering device can also, if desired, be 
solution in the parenteral container. coupled to the container 10. Additionally, a clamshell (not 
Although the third port 24 is described as a separate shown) or other structure can be used that circumscribes the 
element with respect to the sterilizing filter 28, it should be 45 flexible container 10. The clamshell can be designed to only 
appreciated that the third port 24 can be an integral part of allow the container. 10 to accept a predetermined amount of 
the filter. fluid. 
In an embodiment, the sterilizing filter 28 is removably As illustrated, the prefilled syringe 38 includes a plunger 
secured to the container 10. To this end, a h e r  connection or 42 designed to move in a piston motion within an interior of 
the like can be used to removably secure the filter to the the body 44 of the syringe 42. Of course, by moving the 
container. This allows the sterilizing filter 28 to be removed plunger 42 toward the end of the body 44 of the syringe, the 
after the parenteral solution has been created in the con- solute within the syringe body is expelled. Preferably, the 
tainer. To accomplish this, a bidirectional valve can be syringe 38 terminates in  a blunt end 46. The blunt end 46 of 
located between the container and the filter so that when the 55 the syringe 36 can either include a cap or other protective 
filter is removed, fluid does not flow out of the container. covering that is removed prior to use. 
The advantage of this structure, in part, is with respect to In the preferred embodiment illustrated, a pin 47 is 
long term storage of the resultant parenteral solution con- provided that is received within apertures 48 in the syringe 
taining containers. If stored for a long period of time, there body 44 and plunger 42 preventing inadvertent movement of 
is a potential for growth through the filter that could poten- 60 the plunger and thereby an inadvertent discharge of the 
tially contaminate the solution in the containers. solute from the syringe. 
The third port 24 is designed so that it can be coupled to The syringe 38 is designed to dock with the fourth port 34. 
a sterile water source 32. The sterile water source 32 is Because the fourth port 34 includes a one-way valve, this 
designed so that it can pump sterile water into the interior 16 establishes fluid communication and the solute can be 
of the container 10. The sterile water source 32 can be any 65 injected through the fourth port 34, and specifically, through 
apparatus that creates sterile water that can be fed into the the one way valve, into the interior 16 of the container 10. 
container. For example, the sterile water source 32 can be the Once the solute is injected into the container 10, the syringe 
5,490,848 
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38 can be removed because the one way valve prevents the 
solute and the parenteral solution from exiting the port. 
When the solute has been so injected into the container 10 
it can mix with the sterile water that is injected into the 
container from the sterile water source. This allows 
parenteral solutions to be created as necessary in an expe- 
dient manner. 
Referring now to FIG. 2, an embodiment of the system is 
illustrated. The structure is substantially similar to the struc- 
ture set forth in FIG. 1 except that the prefilled syringe 138 
is designed to dock with the container 110 by being received 
within a depressed port 134 in the container 110. The 
depressed port 134 includes a frangible seal member 135. 
Additionally, the depressed port 134 includes means for 
locking the syringe 138 to the port, and therefore the 
container 110. 
Accordingly, once the syringe 138 docks with the 
depressed port 134 and the pin 147 is removed, the plunger 
142 can be pushed downwardly causing a seal on the syringe 
to rupture as well as the seal 135 on the container 110. This 
allows the solute 140 to be injected into the interior 116 of 
the container 110. Because the syringe 138 and depressed 
port 134 are designed so that once the syringe docks with the 
container it remains securely fastened thereto, the syringe 
138 remains attached to the container 110 during the cre- 
ation of the parenteral solution and use of the product, Le., 
infusion of the solution into a patient. 
Referring now to FIG. 3, a further embodiment of the 
present invention is illustrated. Again, a large volume empty 
parenteral container 210 is provided. As in the previous 
embodiments, the solute and sterile water are added to the 
container to create a parenteral solution. To this end, in the 
illustrated embodiment, a plurality of ports are provided. 
Again, a medicament port 214, for adding a medicament, 
is provided. Additionally, an administration port 220 from 
which solution can be administered to the patient is pro- 
vided. In the illustrated embodiment, a redundant or extra 
port 223 is provided. Of course, this port 223 is not neces- 
sary but functions to provide additional means for accessing 
the container. 
Similar to the previous embodiments, a third port 224 is 
provided having a sterilizing filter 228 that is connected at 
one end to the large volume parenteral container 210 and at 
the other end to the port 224. Again, a fluid path is defined 
from the port 224, through the filter 228, and into the interior 
216 of the container 210. 
In this embodiment of the system, a second container 250 
is provided. The second container 250 houses the solute 252. 
Again, the solute can be a liquid concentrate or a powder for 
creating a parenteral solution, e.g., saline, dextrose, or 
lactated Ringer’s. 
The second container 250 includes a first coupling mem- 
ber 254 and a second coupling member 256. The first 
coupling member 254 is designed to couple with the third 
8 
port 224 of the large volume container 210 providing fluid 
communication between the interior 216 of the second 
container 250 and the third port 224. Thus, fluid flow is 
established between the interior of the second container and 
5 the filter 228 and interior 216 of the container 210. 
The second coupling member 256 of the second container 
250 is designed to couple with a sterile water source 230. 
The second coupler 256 allows fluid to flow from the sterile 
water source 230 through the second container 250 wherein 
it can mix with the liquid concentrate or powder contained 
therein. The resultant mixture then flows through the ster- 
ilizing filter 228. As the resultant fluid flows through the 
filter 228, it is filtered. It has been found that even if a 
15 powder is used, a 0.22 micron filter will not become clogged 
if properly wetted. From the filter 228, the solution flows 
into the container 210 wherein the solution can create a 
parenteral solution in a large volume parenteral container. 
In each of the first and second coupling members, one 
2o way valves are provided. This allows fluid to flow in only 
one direction, toward the interior 216 of the container 210. 
Referring to FIG. 4, an embodiment of the second con- 
tainer 350 is illustrated. As illustrated, channels 355 are 
25 provided within the container to ensure that the sterile water 
flow flushes the solute out of the bag. The channels 355 
create fluid flow paths (illustrated by arrows) that are 
designed to insure that there is a mixing and flow of the 
solute out of the second container into the large volume 
30 parenteral container. The channels 355 can be created in a 
number of ways, for example, by ridge members sealed 
within an interior 316 of the container or sealing portions of 
the body of the container to each other. 
Referring to FIG. 5, a further embodiment of the second 
35 container 450 is illustrated wherein a circular flow path 
(illustrated by an arrow) is provided. The container includes 
a divider 451 at the center 453 of its interior 455 to define 
a flow path. Fhid is accelerated at the top 456 of the arc 
through constriction and aids in the mixing. 
Referring now to FIG. 6, a further, preferred, embodiment 
of the second container 550 is illustrated. In the embodiment 
illustrated, a serpentine flow path is provided. The second 
container 550 effectively consists of a long, narrow serpen- 
tine path that forces complete mixing of the solute and sterile 
45 water within the second container 550. This ensures com- 
plete mixing of the solute and sterile water. The length of the 
fluid path (i.e., number of times the serpentine path reverses 
itself) assists in insuring complete mixing. Again, first and 
second coupling members 554 and 556 are provided. 
By way of example and not limitation, examples of the 
present invention will now be given. 
Examples of the system of the present invention are as 
follows. These examples allow for the creation of lactated 
Ringer’s, normal saline, half-normal saline, and 5% dex- 
trose. 
40 
Approximate Approximate Approximate 
Approximate Weight Volume Weight (Fill- 
Volume (Solute) (Package) ed Pack- 
Embodiment (Solute) ml grams ml age) grams 
Powder in second 
container 
Lactated Ringer’s 
Normal Saline 
- - - - 
6.41 9.00 109.96 43.80 
5,490,848 
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Approximate Approximate Approximate 
Approximate Weight Volume Weight (Fill- 
Volume (Solute) (Package) ed Pack- 
Embodiment (Solute) ml grams ml age) grams 
Half-Normal Saline 
5% Dextrose 
Concentrate in second 
container 
Lactated Ringer’s 
Normal Saline 
Half-Normal Saline 
5% Dextrose 
Powder in syringe 
Lactated Ringer’s 
Normal Saline 
Half-Normal Saline 
5% Dextrose 
Concentrate in syringe 
Lactated Ringer’s 
Normal Saline 
Half-Normal Saline 
5% Dextrose 
3.24 
45.00 
4.50 
45.50 
106.72 
159.94 
39.30 
84.80 
40.00 
50.00 
25.00 
71.40 
47.7 
58.10 
29.05 
91.60 
218.00 
218.00 
218.80 
147.00 
106.00 
106.00 
102.80 
147.00 
- 
6.47 
3.24 
45.00 
- 
9.00 
4.50 
45.50 
- 
31.46 
28.22 
188.29 
- 
16.90 
12.40 
89.20 
40.00 
50.00 
25.00 
71.40 
47.7 
58.10 
29.05 
91.60 
188.29 
188.29 
163.29 
301.19 
95.00 
97.30 
68.25 
144.64 
25 The measured densities and weights of concentrates at -continued 
I 
Embodiment Utilizing Syringe - Powder target fill volumes used in the above examples are as 
follows: 
Proposed 30 
Density at Solution 
Formulation 25” C. (g/cc) Volume (mL) Weight (g) 
Calculations 
Target Bags 235.0 mL 28200.00 mL 68.38% 
5% Dextrose 188.3 mL 5648.70 mL 13.68% 
Normal 31.5 mL 943.80 mL 2.28% 
Saline 
Half-Normal 28.2 mL 846.00 mL 2.06% 9 g/50 mL 1.162 50 58.1 
Sodium Chloride 
70% Dextrose 1.283 71.4 91.6 35 
Concentrate B* 
Lactated Ringer’s 1.153 50 57.6 
Concentrate C* 
Lactated Ringer’s 1.193 40 47.7 
Saline 
Lactated 188.3 mL 5648.70 mL 13.68% 
Ringer’s 
Total Volume 41287.20 mL 100.00% 
*5.94 gm sodium chloride, 0.297 potassium chloride, 0.198 mg calcium 40 Alternatively, if a liquid concentrate is used in the syringe 
chloride dihydrate, 3.07 gm sodium lactate. embodiment. 
The present invention provides the ability to create, as 
needed, a substantial supply of parenteral solutions using Embodiment Utilizing Syringe - Liquid Concentrate 
initial supplies that have a limited weight and volume. 
For example, based on the above, the following volumes 
and weights are only needed to afford one the ability to 
create 120 one liter parenteral containers, exclusive of the 
sterile water source. 
45 Weight 
Calculations 
65.0 GramsNnit 7800 Grams 39.09% 
144.6 GramsNnit 4339 Grams 21.74% 
Target Bags 
5% Dextrose 
Normal 97.3 GramsNnit 2919 Grams 14.63% 
Total one liter solutions that can be created 120-30 5o Saline 
dextrose, 30 sodium chloride, 30 50% sodium chloride, and 68.3 GramsNnit 2048 Grams 10.26% 
Saline 
Lactated 95.0 GramsNnit 2850 Grams 14.28% 30 lactated Ringer’s: 
Ringer’s 
Embodiment Utilizing Syringe - Powder Total Weight 19956 Grams 100.00% 
55 Volume 
Weight Calculations 
Calculations 
Target Bags 
5% Dextrose 
Normal 
Saline 
Half-Normal 
Saline 
Lactated 
Ringer’s 
Volume 
71.7 GramsNnit 
89.2 GramsNnit 
16.9 GramsNnit 
12.4 GramsNnit 
95.0 GramsNnit 
8600 Grams 
2676 Grams 
507 Grams 
372 Grams 
57.32% 
17.83% 
3.38% 
2.48% 
Target Bags 229.7 mL 
5% Dexeose 301.2 mL 
Normal 188.3 mL 
60 Saline 
Half-Noimal 188.3 mL 
Saline 
Lactated 188.3 mL 
27560.40 mL 51.47% 
9035.70 mL 16.88% 
5648.70 mL 10.55% 
5648.70 mL 10.55% 
5648.70 mL 10.55% 
2850 Grams 18.99% 
Ringer’s 
65 Total Volume 53542.20 mL 100.00% 
Total Weight 15005 Grams 100.00% 
If the embodiment utilizing the second container is used: 
5,490,848 
Embodiment Utilizing Second Container - Powder 
Weight 
Calculations 
Target Bags 65.0 GramsNnit 7800 Grams 48.70% 
5% Dextrose 84.8 GramsllJnit 2544 Grams 15.88% 
Normal 43.8 GramsNnit 1314 Grams 8.20% 
Saline 
Half-Normal 39.3 GramsNnit 1179 Grams 7.36% 
Saline 
Lactated 106.0 GramsNnit 3180 Grams 19.85% 
Ringer’s 
Volume 
Calculations 
Target Bags 229.7 mL 27560.40 mL 60.71% 
5% Dextrose 159.9 mL 4798.20 mL 10.57% 
Normal 110.0 mL 3298.80 mL 7.27% 
Saline 
Half-Normal 106.7 mL 3201.60 mL 7.05% 
Saline 
Lactated 218.0 mL 6540.00 mL 14.41% 
Ringer’s 
Total Weight 16017 Grams 100.00% 
Total Volume 45399.00 mL 100.00% 
Alternatively, if the liquid concentrate is used with the 
second container embodiment: 
Embodiment Utilizing Second Container - Concentrate 
Weight 
Calculations 
Target Bags 
5% Dextrose 
Normal 
Saline 
Half-Normal 
Saline 
Lactated 
Ringer’s 
Volume 
Calculations 
Target Bags 
5% Dextrose 
Normal 
Saline 
Half-Normal 
Saline 
Lactated 
Ringer’s 
65.0 GramsNnit 7800 Grams 37.36% 
147.0 GramsNnit 4410 Grams 21.12% 
106.0 GramsNnit 3180 Grams 15.23% 
77.0 GramsNnit 2309 Grams 11.06% 
106.0 GramsNnit 3180 Grams 15.23% 
Total Weight 20879 Grams 100.00% 
229.7 mL 27560.40 mL 50.74% 
263.0 mL 7890.00 mL 14.52% 
218.0 mL 6540.00 mL 12.04% 
193.0 mL 5790.00 mL 10.66% 
218.0 mL 6540.00 mL 12.04% 
Total Volume 54320.40 mL 100.00% 
By way of further illustration, the data below illustrates 
the ability to create 120 one liter solutions each of dextrose, 
sodium chloride, 50% sodium chloride, or lactated Ringer’s: 
Embodiment Using Second Container - Powder 
Weight 
Calculations 
Target Bags 65.0 GramsNnit 7800 Grams 19.18% 
5% Dextrose 84.8 GramsNnit 10176 Grams 25.02% 
Normal 43.8 GramsNoit 5256 Grams 12.92% 
Saline 
Half-Normal 39.3 GramsNnit 4716 Grams 11.60% 
Saline 
5 
10 
15 
20 
25 
30 
35 
40 
45 
50 
55 
60 
65 
12 
-continued 
Embodiment Using Second Container - Powder 
Lactated 106.0 GramsAJnit 12720 Grams 31.28% 
Ringer’s 
Volume 
Calculations 
Target Bags 229.7 mL 27560.40 mL 27.86% 
5% Dextrose 159.9 mL 19192.80 mL 19.40% 
Normal 110.0 mL 13195.20 mL 13.34% 
Saline 
Half-Normal 106.7 mL 12806.40 IL 12.95% 
Saline 
Lactated 218.0 mL 26160.00 mL 26.45% 
Ringer’s 
Total Weight 40668 Grams 100.00% 
Total Volume 98914.80 mL 100.00% 
Alternatively, if a liquid concentrate is used: 
~~ 
Embodiment Using Second Container - Concentrate 
Weight 
Calculations 
Target Bags 
5% Dextrose 
Normal 
Saline 
Half-Normal 
Saline 
Lactated 
Ringer’s 
Volume 
Calculations 
Target Bags 
5% Dextrose 
Normal 
Saline 
Half-Normal 
Saline 
Lactated 
Ringer’s 
65.0 GramsRlnit 
147.0 GramsAJnit 
106.0 GramsAJnit 
77.0 GramsAJnit 
106.0 GramsAJnit 
Total Weight 
229.7 mL 
263.0 mL 
218.0 mL 
193.0 mL 
218.0 mL 
Total Volume 
7800 Grams 12.98% 
17640 Grams 29.34% 
12720 Grams 21.16% 
9234 Grams 15.36% 
12720 Grams 21.16% 
60114 Grams 100.00 
27560.40 mL 20.48% 
31560.00 mL 23.45% 
26160.00 mL 19.44% 
23160.00 mL 17.21% 
26160.00 mL 19.44% 
134600.40 mL 100.00% 
If the syringe embodiment is used: 
Embodiments Using Syringe - Powder 
Weight 
Calculations 
Target Bags 
5% Dextrose 
Normal 
Saline 
Half-Normal 
Saline 
Lactated 
Ringer’s 
Volume 
Calculations 
71.7 GramsNnit 
89.2 GramsRlnit 
16.9 GramsAJnit 
12.4 GramsRlnit 
95.0 GramsAJnit 
Total Weight 
8600 Grams 25.13% 
10704 Grams 31.28% 
2028 Grams 5.93% 
1488 Grams 4.35% 
11400 Grams 33.31% 
34220 Grams 100.00% 
Target Bags 
5% Dextrose 
Normal 
Saline 
Half-Normal 
235.0 mL 
188.3 mL 
31.5 mL 
31.5 mL 
28200.00 mL 34.84% 
22594.80 mL 27.92% 
3775.20 mL 4.66% 
3775.20 mL 4.66% 
5,490,848 
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Embodiments Using Syringe - Powder 
14 
13. Purge set and connect set to patient. 
14. Begin flow of IV solution to patient. 
Saline 
Lactated 188.3 mL 22594.80 mL 27.92% 
Ringer’s 
Total Volume 80940.00 mL. 100.00% 
Alternatively, if a liquid concentrate is used 
Embodiment Using Syringe - Liquid Concentrate 
Weight 
Calculations 
Target Bags 
5% Dextrose 
Normal 
Saline 
Half-Normal 
Saline 
Lactated 
Ringer’s 
Volume 
Calculations 
Target Bags 
5% Dextrose 
Normal 
Saline 
Half-Normal 
Saline 
Lactated 
Ringer’s 
65.0 GramsAJnit 
144.6 GramsAJnit 
97.3 GramsAJnit 
68.3 GramsAJnit 
95.0 GramsAJnit 
Total Weight 
229.7 mL 
301.2 mL 
188.3 mL 
188.3 mL 
188.3 mL 
Total Volume 
7800 Grams 13.82% 
17357 Grams 30.76% 
11676 Grams 20.69% 
8190 Grams 14.52% 
11400 Grams 20.20% 
56423 Grams 100.00% 
27560.40 mL 20.96% 
36142.80 mL 27.49% 
22594.80 mL 17.18% 
22594.80 mL 17.18% 
22594.80 mL 17.18% 
131487.60 mL 100.00% 
Examples of methods of the present invention are as 
follows: 
POWDER IN FLOW-THROUGH SECOND 
CONTAINER 
1. Remove container from foil pouch (preferably the 
2. Remove second container from foil pouch. 
3. Remove port protector from inlet port on filter of 
container. 
4. Remove port protector from the port of second con- 
tainer. 
5. Connect port of second container to inlet on port on 
filter. 
6. Connect outlet of sterile water source to remaining port 
on second container. 
7. Initiate flow of water from sterile water source into 
second container and then into the container. Filling 
will take approximately 10 minutes. 
containers are stored in foil pouches). 
8. Allow container to fill. 
9. If desired, a medicament can be added by connecting a 
prefilled syringe containing prescribed medication and 
injecting medication to the medication port into the 
container. 
10. After the container is filled, disconnect the second 
container from the sterile water source. 
11. Disconnect the container from second container. 
12. Connect outlet port of container to inlet of adminis- 
tration set. 
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LIQUID CONCENTRATE IN FLOW-THROUGH 
SECOND CONTAINER 
1. Remove container from foil pouch. 
2. Remove second container from foil pouch. 
3. Remove port protector from inlet port on filter of 
container. 
4. Remove port protector from port of second container. 
5. Connect port of second container to inlet on container 
6. Connect outlet of sterile water source to remaining port 
7. Initiate flow of water through sterile water source. 
8. Allow container to fill. 
9. Again, if desired, medication can be added to the 
solution and container. 
10. After container is filled, disconnect second container 
from sterile water source. 
11. Disconnect second container from container. 
12. Remove port protector from outlet port of container. 
13. Connect outlet port of container to inlet of adminis- 
14. Purge set and connect set to patient. 
15. Begin flow of IV solution to patient. 
filter. 
on second container. 
Filling will take approximately 10 minutes. 
tration set. 
POWDER IN SYRINGE 
1. Remove container from foil pouch. 
2. Remove port protector from inlet port on filter. 
3. Connect outlet of sterile water source to inlet port on 
filter. 
4. Initiate flow of water through sterile water source into 
the container. Filling will take approximately 10 min- 
utes. 
5. Allow container to fill. 
6. Remove port protectors from syringe docking site and 
7. Snap end of syringe into docking site. Syringe will lock 
8. Connect plunger handle to plunger of syringe 
9. Remove retaining pin from barrel of syringe. 
10. Depress plunger of syringe, injecting solute into 
container. 
11. If desired, a medicament can be added. To this end, a 
prefilled syringe containing prescribed medication is 
connected to the medication port. 
12. Inject medication into the container. 
13. After container is filled, disconnect container from 
14. Remove port protector from inlet of administration 
15. Connect outlet port of LVP to inlet of administration 
from syringe containing proper solute. 
into place. 
sterile water source. 
set. 
set. 
15 
16. Purge set and connect set to patient. 
17. Begin flow of IV solution to patient. 
5,490,848 
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CONCENTRATE IN SYRINGE 
1. Remove container from foil pouch. 
2. Remove port protector from inlet port on filter. 
3. Connect outlet of sterile water source to inlet port on 
4. Initiate flow of water through sterile water source. 
5. Allow container to fill. 
6. Remove port protectors from container injection site 
and from syringe containing proper solute. 
7. Connect syringe to injection site. 
8. Connect plunger handle to plunger of syringe. 
9. Remove retaining pin from barrel of syringe. 
10. Depress plunger of syringe, injecting solute into bag. 
11. Disconnect syringe from injection site. 
12. Again, if desired, a medicament can be added. 
13. After the container is filled, disconnect the container 
14. Remove port protector from inlet of administration 
15. Connect outlet port of container to inlet of adminis- 
16. Purge set and connect set to patient. 
17. Begin flow of IV solution to patient. 
Initial sterilization of the system, i.e., after the individual 
components are created, but before the resultant parenteral 
solution is created, can be accomplished in a variety of ways. 
For the liquid concentrate embodiments sterilization can be 
accomplished using conventional techniques. To this end, 
the container 10 and second container or prefilled syringe 
solute can be terminally sterilized. 
If powders are used, sterilization is more difficult but it 
may be possible to terminally sterilize the container or 
syringe containing the powder through gamma irradiation. 
However, it is possible to manufacture the powder under 
sterile conditions and then fill the second container or 
prefilled syringe with powder under sterile conditions. 
It should be understood that various changes and modi- 
fications to the presently preferred embodiments described 
herein will be apparent to those skilled in the art. Such 
changes and modifications can be made without departing 
from the spirit and scope of the present invention and 
without diminishing its attendant advantages. It is therefore 
intended that such changes and modifications be covered by 
the appended claims. 
filter. 
Filling will take approximately 10 minutes. 
from the sterile water source. 
set. 
tration set. 
We claim: 
1. A system for creating on site, remote from a sterile 
environment, parenteral solutions in a large volume 
parenteral container for intravenous administration to a 
patient comprising: 
an empty large volume containers including at least one 
port for accessing an interior of the container and 
having a sterilizing filter for sterilizing a fluid fed 
through the port into the container; 
a second container including a solute and having means 
for coupling the second container to the large volume 
container and providing fluid communication therebe- 
tween allowing the solute to be received within the 
interior of the container; and 
a sterile water source including means for placing the 
sterile water source in fluid communication with the 
port and allowing sterile water to flow from the sterile 
water source into the interior of the container. 
2. The system of claim 1 wherein the solute is in a powder 
form. 
3. The system of claim 1 wherein the solute is in a liquid 
concentrate form. 
4. The system of claim 1 wherein the solute is chosen 
from the group consisting of: dextrose; sodium chloride; and 
lo lactated Ringer’s. 
5. The system of claim 1 wherein a parenteral solution 
created is chosen from the group consisting of saline, 
dextrose, and lactated Ringer’s. 
6. The system of claim 1 wherein the second container 
l5 includes a syringe prefilled with solute. 
7. The system of claim 1 wherein the second container is 
so constructed and arranged as to allow sterile water to flow 
through an interior thereof into the interior of the large 
volume container. 
8. The system of claim 1 wherein the large volume 
container includes an additive port and an administration 
port. 
9. The system of claim 1 wherein the sterilizing filter is 
removably secured to the large volume container. 
10. A system for creating on site, remote from a sterile 
environment, parenteral solutions in a large volume 
parenteral container for intravenous administration to a 
patient comprising: 
an empty large volume container including at least two 
ports for accessing an interior of the container, a first of 
the two ports including a sterilizing filter for sterilizing 
a fluid fed through the port into the container; 
a device housing a solute and including means that 
cooperate with a second of the two ports to allow the 
device to be coupled onto the container and fluid 
communication to be established between the interior 
of the container and an interior of the device allowing 
the solute to be injected into the interior of the con- 
tainer; and 
a sterile water source including means for allowing the 
sterile water source to be coupled to the first port and 
fluid communication to be established between the 
fluid source and an interior of the container. 
11. The system of claim 10 wherein the solute is in a 
powder form. 
12. The system of claim 10 wherein the solute is in a 
liquid concentrate form. 
13. The system of claim 10 wherein the solute includes a 
component chosen from the group consisting of: dextrose; 
sodium chloride; and lactated Ringer’s. 
14. The system of claim 10 wherein the device is a 
syringe. 
15. The system of claim 14 wherein the syringe includes 
a blunt end. 
16. The system of claim 14 wherein the syringe includes 
5s means for preventing an inadvertent discharge of the con- 
tents of the syringe. 
17. The system of claim 16 wherein the means includes a 
removable pin that is received within at least one aperture of 
a body of the syringe and one aperture in a plunger of the 
18. The system of claim 14 wherein the second port 
includes means for locking the syringe to the container. 
19. The system of claim 10 wherein the container includes 
an additive port and an administration port. 
20. The system of claim 14 wherein the second port 
includes means for releasably receiving an end of the 
syringe. 
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21. The system of claim 10 wherein the second port 
includes a frangible seal that is so constructed and arranged 
that it ruptures to allow solute to be injected into the 
container. 
22. The system of claim 10 wherein the second port 
includes a one way valve. 
23. The system of claim 10 wherein the first port includes 
a bidirectional valve. 
24. The system of claim 10 wherein the sterilizing filter is 
removably secured to the container. 
25. A system for creating on site, remote from a sterile 
environment, parenteral solutions in a large volume, 
parenteral container for intravenous administration to a 
patient comprising: 
an empty large volume parenteral container having a 
plurality of ports including at least one port for access- 
ing an interior of the container, the port including a 
sterilizing filter for sterilizing a fluid fed through the 
port into the container; 
a second container housing a solute in an interior thereof 
and having a first coupling member for coupling the 
second container to the port and establishing fluid 
communication between the interior of the second 
container and the interior of the large volume parenteral 
container and a second coupling member; and 
a sterile water source for providing sterile water and 
including a coupling member for coupling the sterile 
water source to the second coupling member of the 
second container and establishing fluid communication 
from the sterile water source and the interior of the 
second container. 
26. The system of claim 25 wherein the solute is in a 
powder form. 
27. The system of claim 25 wherein the solute is in a 
liquid concentrate form. 
28. The system of claim 25 wherein the solute includes a 
component chosen from the group consisting of: dextrose; 
sodium chloride; and lactated Ringer’s. 
29. The system of claim 25 wherein the second container 
includes in an interior thereof channels. 
30. The system of claim 25 wherein the second container 
includes an interior that defines a circular fluid flow path. 
31. The system of claim 25 wherein the second container 
includes an interior that defines an elongated serpentine fluid 
flow path. 
32. The system of claim 25 wherein the large volume 
parenteral container includes an additive port and an admin- 
istration port. 
33. The system of claim 25 wherein the port includes a 
one way valve. 
34. The system of claim 25 wherein the port includes a 
bidirectional valve. 
35. The system of claim 25 wherein the sterilizing filter is 
removably secured to the large volume parenteral container. 
36. A method for preparing parenteral solutions on site, 
remote from a sterile environment, comprising the steps of  
providing an empty large volume parenteral container 
including means for allowing the container to receive a 
solute and including a sterilizing filter; 
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coupling a device including a solute to the container; 
causing the solute to enter an interior of the container; 
feeding sterile water into the container so that it flows 
through the sterilizing filter before entering the con- 
tainer; and 
allowing the solute and sterile water to mix and create a 
parenteral solution. 
37. The method of claim 36 comprising the steps of: 
providing the container with two ports; and 
causing the solute to enter the interior of the container 
through one port and the sterile water to enter the 
container through a second port. 
38. The method of claim 36 wherein the sterile water is 
fed into the second container prior to the solute entering the 
second container. 
39. The method of claim 36 wherein the sterile water 
enters the second container contemporaneously with the 
solute. 
40. The method of claim 36 wherein the solute is a 
powder. 
41. The method of claim 36 wherein the solute is a liquid 
concentrate. 
42. The method of claim 36 wherein the solute includes a 
component chosen from the group consisting of dextrose; 
sodium chloride; and lactated Ringer’s. 
43. The method of claim 36 including the step of adding 
a medicament to the parenteral solution. 
44. The method of claim 36 wherein the parenteral 
solution is administered intravenously to the patient. 
45. The method of claim 36 wherein the parenteral 
solution created is chosen from the group consisting of 
dextrose, saline, and lactated Ringer’s. 
46. The method of claim 36 including the step of remov- 
ing the sterilizing filter from the large volume parenteral 
container after the parenteral solution is created. 
47. A method for preparing parenteral solutions on site, 
remote from a sterile environment, comprising the steps of: 
providing an empty large volume parenteral container 
including means for allowing the container to receive a 
solute and including a sterilizing filter; 
coupling a device including a solute to the container; 
causing the solute to enter an interior of the container; 
feeding sterile water into the container so that it flows 
through the sterilizing filter; 
allowing the solute and sterile water to mix and create a 
parenteral solution; and 
providing for the device a second container that is coupled 
to a port and the sterile water source is coupled to an 
end of the second container so that sterile water is fed 
into the interior of the second container and the solute 
and sterile water then flows through the port and the 
filter into the container. 
* * * * *  
